Chan, Calvin C. http://orcid.org/0000-0002-9933-3061
Harley, Isaac T. W. http://orcid.org/0000-0003-1282-5395
Pfluger, Paul T. http://orcid.org/0000-0002-8118-7588
Trompette, Aurelien
Stankiewicz, Traci E.
Allen, Jessica L.
Moreno-Fernandez, Maria E. http://orcid.org/0000-0002-6593-7967
Damen, Michelle S. M. A. http://orcid.org/0000-0003-4617-2564
Oates, Jarren R. http://orcid.org/0000-0002-4734-5597
Alarcon, Pablo C. http://orcid.org/0000-0002-6584-7734
Doll, Jessica R. http://orcid.org/0000-0001-5225-801X
Flick, Matthew J.
Flick, Leah M.
Sanchez-Gurmaches, Joan http://orcid.org/0000-0003-1854-7832
Mukherjee, Rajib http://orcid.org/0000-0002-3509-4997
Karns, Rebekah
Helmrath, Michael
Inge, Thomas H. http://orcid.org/0000-0001-7782-1112
Weisberg, Stuart P. http://orcid.org/0000-0002-8698-5976
Pamp, Sünje J.
Relman, David A. http://orcid.org/0000-0001-8331-1354
Seeley, Randy J. http://orcid.org/0000-0002-3721-5625
Tschöp, Matthias H.
Karp, Christopher L.
Divanovic, Senad http://orcid.org/0000-0001-7538-0499
Article History
Received: 21 June 2019
Accepted: 12 April 2021
First Online: 18 May 2021
Competing interests
: The authors declare the following competing interests. S.D., C.L.K. and J.L.A. hold patents on BAFF and APRIL. S.D. is a consultant for Janssen Research & Development. M.H.T. is a scientific advisor to Novo Nordisk and ERX. R.J.S. is consultant to Novo Nordisk, Sanofi, Scohia, GuidePoint Consultants, Kintai Therapeutics, and Ionis. R.J.S. receives research support or equity from Novo Nordisk, Zafgen, Astra Zeneca, Redesign Health, Ionis and Pfizer. C.C.C., I.T.W., P.F.T., A.T., T.E.S, M.E.M-F., M.S.M.A.D., J.R.O., P.C.A., J.R.D., M.J.F., L.M.F., J.S-G., R.M., R.K., M.H., T.H.I., S.P.W., S.J.P., D.A.R. declare no competing interests.